Back to News
Market Impact: 0.2
Galapagos NV Announces Gamgertamig Preliminary Phase 1b Data and Poster Presentation at 2026 ASH Meeting
Source: Nasdaq
Healthcare & Biotech
Galapagos NV said a poster featuring preliminary data on investigational gamgertamig in relapsed/refractory autoimmune cytopenias was accepted for the 2026 American Society of Hematology Annual Meeting, scheduled for December 12–15. The article provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- CVS Plans to Break Up $117 Billion Healthcare Conglomerate
- How Abdul El-Sayed would build Medicare for All, from a wealth tax to a Fed-style governing board
- BillionToOne SVP John ten Bosch sells $320,723 in stock
- Novo raises full-year outlook as Wegovy sales impress
- Sight Sciences earnings missed by $0.48, revenue topped estimates
- Novo CEO Doustdar 'Very Optimistic' About CagriSema